251945-92-3OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1RBZNJGHIKXAKQE-UHFFFAOYSA-NDerenofylline has been used in trials studying the treatment of Congestive Heart Failure and Acute Decompensated Heart Failure; Renal Dysfunction.
251945-92-3DTXSID30948047CHEMBL4204703、CHEMBL592435안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Derenofylline is an adenosine A1 receptor antagonist (Ki = 1 nM). It is selective for adenosine A1 over A2A, A2B, and A3 receptors (Kis = 398, 3,981, and 200 nM, respectively). It decreases adenosine A1 receptor-mediated adenosine-induced bradycardia in rats (ED50 = 0.49 mg/kg) but reduces A2 receptor-mediated adenosine-induced hypotension by only 44.6% when administered at an intravenous dose of 5 mg/kg. It prevents increases in heart levels of collagen I and III in nephrectomized rats when administered at a dose of 10 mg/kg per day. Derenofylline also reduces relative plaque counts in a Zika virus plaque-forming assay in A549 cells (IC50 = 58.6 nM) in an adenosine A1 receptor-independent manner without inducing cytotoxicity when used at concentrations less than 10 μM.
용도SLV 320 is an A1 antagonist.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…